Trial Profile
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Mar 2023
Price :
$35
*
At a glance
- Drugs Ladiratuzumab-Vedotin (Primary) ; Trastuzumab
- Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
- Focus Adverse reactions
- Sponsors Seagen
- 03 Mar 2023 Status changed from active, no longer recruiting to completed.
- 19 Dec 2022 Planned primary completion date changed from 31 Jul 2022 to 31 Mar 2023.
- 19 Dec 2022 Status changed from recruiting to active, no longer recruiting.